Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets

Mathai Mammen, Parabilis Medicines CEO May 18, 2026 11:33 AM EDT DealsR&D Af­ter key tri­al fail, Re­gen­eron reach­es $125M Para­bilis deal for hard-to-catch drug tar­gets Lei Lei Wu News Reporter As Re­gen­eron’s can­cer port­fo­lio con­tin­ues to suf­fer set­backs, the com­pa­ny is plac­ing a bet in a dif­fer­ent di­rec­tion through a deal with Para­bilis Med­i­cines val­ued … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER